While Pfizer currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys. The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. Pfizer scored higher than 100% of companies evaluated by MarketBeat, and ranked 1st out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

• Enter your email to get this report and avoid a high-yield dividend trap.
• On Oct. 29, 2021, the FDA extended the EUA for the vaccine to include children ages 5–11.
• Today, the stock is trading at a heavily discounted forward price-to-earnings multiple (based on analyst estimates) of less than 9, which suggests that investors are feeling a bit concerned about Pfizer’s future.

Stock Lists

Their success with citric acid led to the company’s expansion and other major discoveries. Discover which analysts rank highest on predicting the directional movement of PFE. Get stock recommendations, portfolio iq option broker review guidance, and more from The Motley Fool’s premium services. Stronger results from its specialty care and oncology segments have helped Pfizer overcome headwinds from the vaccine side of its operations.

This story was reviewed by MarketBeat’s editorial team prior to publication. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period. Pfizer reported revenues of $17.7 billion in the last reported quarter, representing a year-over-year change of +33.8%. Pfizer is expected to post earnings of $0.49 per share for the current quarter, representing a year-over-year change of +390%.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern traderoom medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup. Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Over the last 30 days, the Zacks Consensus Estimate has changed -28.4%. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company’s earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. Albert Bourla, who has been with Pfizer for more than 25 years, is currently the company’s chief executive officer (CEO) and chairman.

The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

And while the markets have done well overall, shares of Pfizer are down some 11% this year. For the next fiscal year, the consensus earnings estimate of $2.92 indicates a change of +0.4% from what Pfizer is expected to report a year ago. For the current fiscal year, the consensus earnings estimate of $2.91 points to a change of +58.2% from the prior year. Albert Bourla is the pharmaceutical giant’s current chief executive officer (CEO). Pfizer is classified as a member of the S&P 500 healthcare sector and operates within the biotechnology and pharmaceutical industry.

New Strong Buy Stocks for November 27th

On Oct. 29, 2021, the FDA extended the EUA for the vaccine to include children ages 5–11. In 2020, Pfizer co-developed with BioNTech SE a vaccine against COVID-19, the virus whose rapid spread prompted the World Health Organization (WHO) to declare a global pandemic in March 2020. On Dec. 11, 2020, the Pfizer-BioNTech vaccine became the first COVID-19 vaccine to receive emergency use authorization (EUA) from the U.S. The vaccine was approved for emergency use for individuals 16 years of age and older. On May 10, 2021, the FDA expanded the EUA for the Pfizer-BioNTech vaccine to include adolescents ages 12–15.

Moderna And Other Vaccine Maker Stocks Tumble After Trump Taps RFK Jr. As HHS Head

When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying attention. That’s why top firms like SoftBank and Maveron have already backed their latest venture, a company that’s transforming the $1.3 trillion vacation home market. World War I caused a shortage of materials for making citric acid and forced the company to seek alpari forex broker review alternatives.

Crypto Stocks to Buy Now: IBIT, COIN, MARA

Another potentially massive opportunity for Pfizer is in the weight loss market, where it’s working on a once-daily pill, which could unlock a significant growth catalyst for the business. The pill, danuglipron, has been showing promise in early-stage trials, and it could be one of the first oral weight loss treatments to obtain approval from regulators in the near future. For Pfizer, the consensus sales estimate for the current quarter of $17.45 billion indicates a year-over-year change of +22.4%. For the current and next fiscal years, $63.31 billion and $62.89 billion estimates indicate +8.2% and -0.7% changes, respectively. According to 13 analysts, the average rating for PFE stock is “Buy.” The 12-month stock price forecast is $33.17, which is an increase of 28.42% from the latest price.

Upgrade to MarketBeat All Access to add more stocks to your watchlist. Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up.

Discover which analysts rank highest for PFE overall weighted by direction, price target, and price movement. The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The business’s fifty day simple moving average is $27.97 and its 200-day simple moving average is $28.52. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.